Ipsen SA (ADR: IPSEY) generates a steady flow of news centered on its activities as a global, mid-sized biopharmaceutical company focused on Oncology, Rare Disease and Neuroscience. This news page aggregates company announcements, partner releases and regulatory updates that mention Ipsen and its ADR program, giving readers a focused view of developments that can influence perceptions of IPSEY.
Recent news highlights Ipsen’s role in advancing specialty care medicines. In oncology, the company has reported Phase III NAPOLI 3 trial results for an investigational Onivyde-based regimen (NALIRIFOX) in previously untreated metastatic pancreatic ductal adenocarcinoma, with statistically significant improvements in overall and progression-free survival compared to a nab-paclitaxel plus gemcitabine regimen. Ipsen has also nominated a first clinical drug candidate from its multi-year oncology collaboration with Marengo Therapeutics, based on Marengo’s STAR T cell activator platform for solid tumors.
In rare diseases, news items cover Ipsen’s work in pediatric cholestatic liver diseases and ultra-rare conditions. Examples include Health Canada’s approval of Bylvay (odevixibat) for pruritus due to Progressive Familial Intrahepatic Cholestasis, under a partnership with Medison Pharma, and regulatory interactions for palovarotene in fibrodysplasia ossificans progressiva, including a CHMP negative opinion and a U.S. FDA Complete Response Letter. Corporate news also details Ipsen’s agreement to acquire Albireo, adding Bylvay and other bile acid modulators to its rare disease portfolio.
Neuroscience and rare neurological disease updates feature Ipsen’s collaboration with Skyhawk Therapeutics to discover RNA-targeting small molecules for rare neurological diseases. Partner announcements describe Ipsen’s option to obtain exclusive global rights to development candidates and its responsibility for later-stage development and commercialization.
Investors and observers can use this news feed to follow Ipsen’s clinical trial readouts, regulatory decisions, licensing deals, acquisitions and capital markets disclosures that reference IPSEY. Regularly reviewing these updates can help contextualize the company’s therapeutic focus and strategic direction as reflected in public announcements.
Ipsen (IPSEY) reported nine-month sales of €3,364.2 million and raised its full-year sales growth and core operating margin guidance. Sales increased 23.0% as reported and 24.6% at constant exchange rates (CER), which exclude currency effects. Third-quarter sales reached €1,173.9 million, up 28.3% as reported and 26.7% at CER.
Ipsen now expects 2026 sales growth around 23.0% at CER, versus greater than 20.0% previously, and core operating margin around 39.0%, versus greater than 37.0%. It expects an adverse currency effect around 0.5% on sales. Oncology, Rare Disease and Neuroscience all recorded nine-month growth. Completed acquisitions of Memo Therapeutics and Kartos Therapeutics added potravitug and navtemadlin. Regulatory submissions are underway for Dysport in migraine and Iqirvo in primary biliary cholangitis.
Ipsen (IPSEY) reported 83,814,526 shares composing its share capital as of 30 September 2026 in its monthly voting-rights disclosure.
Gross voting rights totaled 132,065,045, including double voting rights and treasury shares. Net voting rights, excluding shares without voting rights, totaled 130,667,557. The gross total is the basis for calculating threshold crossings.
Ipsen (IPSEY) repurchased 46,805 shares under its buy-back programme on September 21 and 22, 2026.
The reported overall weighted average purchase price was 147.0812 per share. Purchases were reported on XPAR, CEUX, AQEU and TQEX, with separate daily volumes and weighted average prices listed for each market.
Ipsen (IPSEY) reported share repurchases under its buy-back programme for the week of 14–18 September 2026, totaling 25,000 shares at a weighted average purchase price of €155.4376 per share.
No shares were repurchased on 14, 15 or 16 September. On 17 September, purchases were executed across XPAR, CEUX, TQEX and AQEU at prices around €155.2–€155.8, and on 18 September on XPAR and CEUX at about €156.1–€156.3 per share.
Ipsen (IPSEY) has appointed Mariette Finet to its Board of Directors by co‑optation, effective immediately, following the resignation of Director Michèle Ollier on 1 August 2026. Finet, a medical doctor and University of Nancy graduate, brings more than 35 years of experience in healthcare, pharmaceuticals and life sciences. She began her career in the Medical Department of Laboratoires Beaufour, later holding marketing roles at Beaufour‑Ipsen Pharma and Ipsen, and since 2007 has advised Mayroy and Highrock S.àr.l. on investment and portfolio oversight in pharmaceutical, MedTech and life sciences sectors. She has also served on the boards of Lightinderm SAS and Kaerus Bioscience Ltd. The Board has named Finet to the Board Portfolio Committee, succeeding Ollier. Her appointment will be submitted for ratification at the next Annual Shareholders’ Meeting, to complete Ollier’s term through approval of the 2026 financial statements. The Board remains at 14 members, evenly split between seven women and seven men, and includes four independent directors and two employee representatives.
Ipsen (IPSEY) reports weekly share repurchases under its buy-back programme for the period from 31 August to 4 September 2026.
The company repurchased a total of 11,270 shares of ISIN FR0010259150 at a total daily volume weighted average purchase price of 162.8198 per share. Purchases were executed mainly on XPAR (8,081 shares at 162.4041 and 1,270 shares at 164.2308) and on CEUX (1,919 shares at 163.6365). No repurchases were recorded on 1, 2 or 3 September 2026.
Ipsen (IPSEY) reported share repurchases under its buy-back programme for the week of 31 August to 4 September 2026.
The company bought a total of 11,270 shares of instrument FR0010259150 at a daily weighted average price of €162.8198. Purchases were executed mainly on 31 August 2026 on XPAR and CEUX, with an additional transaction on 4 September 2026 on XPAR. No shares were repurchased on 1, 2 and 3 September 2026.
Ipsen (IPSEY) reported its monthly share capital and voting rights as of 31 August 2026. The company had 83,814,526 shares outstanding, with a gross total of 132,077,444 voting rights and a net total of 130,818,157 voting rights, in line with French regulatory requirements.
Ipsen (OTC: IPSEY) reported share repurchases under its buy-back programme in compliance with Article 5 of MAR for week 35 of 2026. From 24 to 28 August 2026, Ipsen bought back 3,645 shares on XPAR on 24 August at a daily weighted average price of €161.1922 per share, with no repurchases on the remaining days.